Raub Brock Capital Management’s Pfizer PFE Stock Holding History

Raub Brock Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,851	Closed	-$402K	–	69
2023 Q1	$402K	Buy	9,851 +3,500	+55%	+$151K	0.08%	42
2022 Q4	$325K	Hold	6,351	–	–	0.07%	49
2022 Q3	$278K	Hold	6,351	–	–	0.06%	51
2022 Q2	$333K	Hold	6,351	–	–	0.06%	45
2022 Q1	$329K	Buy	+6,351	New	+$330K	0.06%	54

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raub Brock Capital Management's PFE Position: Q2 2023 in Review

Raub Brock Capital Management sold out of Pfizer (PFE) in Q2 2023, closing a stake of 9,851 shares — an estimated $402K sold.

Raub Brock Capital Management first reported a position in PFE in Q1 2022 and held it in 5 quarters. The position peaked at $402K in Q1 2023. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Raub Brock Capital Management reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Raub Brock Capital Management sold 9,851 Pfizer shares in Q2 2023, an estimated $402K.
Raub Brock Capital Management first reported a position in Pfizer in Q1 2022 and held it in 5 quarters.
Raub Brock Capital Management's Pfizer position peaked at $402K in Q1 2023.
3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Raub Brock Capital Management's 13F filing for Q2 2023, filed 26 Jul 2023.